KPV

KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) studied for its potent anti-inflammatory properties without melanotropic side effects.

Profile · 01

Overview

KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) studied for its potent anti-inflammatory properties without melanotropic side effects. It reduces pro-inflammatory cytokines and modulates immune cell activity through inhibition of NF-kB signaling. It is not FDA-approved for any indication and remains a research peptide. Preclinical models demonstrate efficacy in inflammatory bowel disease, colitis, and systemic inflammation contexts, though human clinical data are limited. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Support anti-inflammatory processes, gut health, and immune modulation
Categories
Anti-InflammatoryGut HealthImmune ModulationTissue Repair
Synergistic
BPC-157 · GHK-Cu · Thymosin Alpha-1 · Omega-3 fatty acids
Profile · 02

Protocol

Suggested daily titration approach starting low and increasing weekly over four weeks.

Typical daily range
200–500 mcg once daily (gradual titration)
Start
200 mcg daily; increase by ~100 mcg weekly as tolerated
Target
500 mcg daily by Week 4
Frequency
Once per day (subcutaneous)
Cycle Length
8–12 weeks; optional extension to 16 weeks
Timing
Any consistent time; rotate injection sites
Route
Subcutaneous
Cycle
8–12 weeks on, 4 weeks off

Inject once daily subcutaneously using a dilution that maintains accuracy at small volumes. KPV's anti-inflammatory mechanism via NF-kB inhibition is distinct from hormonal pathways, making it well suited for inflammatory and gut-health protocols. Dosing derives from preclinical models; human clinical validation remains limited.

Dose progression

Week 1
200 mcg (0.2 mg)
Week 2
300 mcg (0.3 mg)
Week 3
400 mcg (0.4 mg)
Weeks 4–8
500 mcg (0.5 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How KPV works.

KPV is the C-terminal tripeptide fragment of alpha-MSH, retaining the parent hormone's potent anti-inflammatory activity while eliminating melanotropic (skin pigmentation) side effects. Its primary mechanism involves inhibition of nuclear factor kappa B (NF-kB) signaling and modulation of inflammatory mediator release. Preclinical studies demonstrate that KPV reduces pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. Notably, KPV shows activity via both oral and subcutaneous routes in animal models. Its potential for tissue repair and wound healing is attributed to downstream effects of inflammatory modulation. However, large-scale controlled human clinical data remain unavailable.

Science · 02

Effects

Observations from clinical or preclinical literature.

Potent reduction of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) in IBD and systemic inflammation models (preclinical data)
Demonstrates activity via both oral and subcutaneous routes (preclinical data)
Potential tissue repair and wound healing support through inflammatory modulation (preclinical data)
No melanotropic effects on skin pigmentation — a key advantage over full-length alpha-MSH
Generally well tolerated in research protocols with no systemic side effects commonly reported
Occasional mild injection-site reactions (redness, slight swelling) may occur with subcutaneous administration
Long-term human safety and efficacy remain under investigation
Science · 03

Caution

Not recommended during pregnancy or breastfeeding (no safety data available)
Individuals with autoimmune conditions should consult a healthcare provider, as immune modulation may have unpredictable effects
Use with caution in individuals on immunosuppressive medications due to potential interactions
KPV is a research peptide not approved by regulatory agencies for human therapeutic use
Consult qualified healthcare professionals before beginning any peptide protocol

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Omega-3 fatty acids
Support anti-inflammatory pathways complementary to KPV's NF-kB inhibition mechanism.
Probiotics
Support gut microbiome health, relevant when targeting inflammatory bowel conditions.
Zinc
Supports immune function and gut lining integrity.
Vitamin D
Supports immune regulation and inflammatory modulation.
Glutamine
Supports gut mucosal barrier integrity and repair.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Follow an anti-inflammatory diet emphasizing whole foods, omega-3s, and polyphenols
Engage in regular moderate physical activity to support systemic anti-inflammatory tone
Prioritize 7–9 hours of quality sleep nightly to support immune regulation and recovery
Practice stress management through meditation, yoga, or similar modalities; chronic stress amplifies inflammatory signaling
Support the microbiome through probiotics and dietary fiber
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Digestive symptoms (bloating, pain, stool quality) — monitor daily to gauge gut-health response
  2. Systemic inflammation signs (joint stiffness, fatigue, skin flares) — track to identify anti-inflammatory trends
  3. Energy levels and general well-being — improvements may reflect reduced inflammatory burden
  4. Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)
General inflammation marker; track before and during protocol.
ESR (Erythrocyte Sedimentation Rate)
Secondary inflammation marker to corroborate CRP trends.
Fecal calprotectin
Specific marker for intestinal inflammation; relevant for gut-health protocols.
CBC (Complete Blood Count)
Monitor overall health and immune cell counts.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry completely (10–15 seconds)
Pinch a 1–2 inch skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds
Withdraw smoothly; apply gentle pressure with clean alcohol swab (do not rub)
Rotate sites systematically (abdomen at least 2 inches from navel, anterior/lateral thigh, outer upper arm) spacing at least 1–2 inches apart to avoid lipohypertrophy
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly (over 3–5 seconds); wait a few seconds before withdrawing the needle
Document daily dose and site rotation to maintain consistency
KPV is a research peptide not approved by regulatory agencies for human therapeutic use; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. Annals of the New York Academy of Sciences
    Brzoska T et al., "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects".
    https://pubmed.ncbi.nlm.nih.gov/18573475/
  2. Journal of Biological Chemistry
    Mandrika I et al., "Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB signaling".
    https://pubmed.ncbi.nlm.nih.gov/11278567/
  3. Inflammatory Bowel Diseases
    Kannengiesser K et al., "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease".
    https://pubmed.ncbi.nlm.nih.gov/18985746/
  4. PLoS One
    Dalmasso G et al., "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation".
    https://pubmed.ncbi.nlm.nih.gov/18716660/
  5. Peptides
    Catania A et al., "The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro".
    https://pubmed.ncbi.nlm.nih.gov/8637519/
  6. Journal of Leukocyte Biology
    Getting SJ et al., "Melanocortin peptides and their receptors: anti-inflammatory potential in wound healing".
    https://pubmed.ncbi.nlm.nih.gov/16769764/
  7. WHO (NCBI Bookshelf)
    "Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)".
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
  8. Johns Hopkins Arthritis Center
    "How to give a subcutaneous injection (patient education resource)".
    https://www.hopkinsarthritis.org/patient-corner/how-to-give-a-subcutaneous-injection/
  9. CDC
    "Vaccine administration: subcutaneous route (angle/site; no aspiration)".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  10. PMC
    "Subcutaneous drug injection review and site rotation practices".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page